hotspot -WSS

hotspot

author：comprehensive 2025-09-06 02:13:49 - browse：45547

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： More hospitals are billing patients as online messages surge

WSS

FDA seeking to stop procedures at two unregulated stem cell clinics

With heat waves through August, officials warn of health risks

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Doctors are clamoring for more clarity on Paxlovid prescribing

A strong 6.5

'Brian's Song' at 50 still offers lessons about cancer for today

entertainment

hotspot

hotspot

Drug repurposing or repositioning? The language matters

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

United colonoscopy coverage change 'may cost lives,' doctors say

Doctors are clamoring for more clarity on Paxlovid prescribing

DIEP, the 'gold standard' of breast reconstruction, is under threat

'Brian's Song' at 50 still offers lessons about cancer for today

State Dept. review finds Biden bears some blame for Afghanistan failures

St. Louis police protesters begin picking up checks in $4.9 million settlement

Jerome Adams on the need for new antivirals for Covid

Slovenia has suffered its worst

leisure time

St. Louis police protesters begin picking up checks in $4.9 million settlement

Flagship, Pfizer team up in deal worth up to $7 billion

Restaurant meals are packed with calories, and we still keep eating them

A Theranos scientist

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

15 die by electrocution after transformer explodes in northern India

entertainment

hotspot

hotspot

hotspot